Development of Pre-Erythrocytic Malaria Vaccines

今年的主要发现如下。 1.结果表明，辐射可减弱NHP内注射的子孢子在血液和肝脏中诱导的强大的CD4和CD8T细胞反应。证实肝脏中高频率的NK细胞在刺激时分泌干扰素-g，为保护提供了额外的效应细胞。单核细胞和树突状细胞向T细胞递呈SPZ抗原。 2.完成了一项I期临床试验，在剂量递增研究中评估由IV路线给予的辐照PfSPZ是否安全和具有保护作用。 3.表明减毒疟疾疫苗(PfSPZ疫苗)在人类受到疟疾感染的实验性挑战后提供了高水平的保护。 4.表明PfSPZ疫苗的剂量对介导免疫和保护至关重要。

The major discovery this year are as follows. 1. Showed that radiation attenuated sporozoites administered intravenously into NHP induced potent CD4 and CD8+ T cell responses in blood and liver. Established that a high frequency of NK cells in the liver secrete IFN-g in response to stimulation providing an additional effector cell for protection. Furthermore, showed that monocytes and dendritic cells present SPZ antigen to T cells. 2. Completed a phase I clinical trial assessing whether irradiated PfSPZ given by the IV route is safe and protective in a dose escalation study. 3. Showed that an attenuated malaria vaccine ( PfSPZ Vaccine) confers high level protection in humans following an experimental challenge with malaria infection. 4. Showed that the dose of the PfSPZ Vaccine is critical for mediating immunity and protection.